Dermapharm Holding stock | Price target for 2026, price & analyst rating

Dermapharm Holding

XTRA:DMP

€ 47,25

€0,00 (0,00%)

47,25 €

€0,00 (0,00%)

End-of-day quote: 04/03/2026

Dermapharm Holding Stock Value

The analyst rating for XTRA:DMP is currently Outperform.

Outperform

Dermapharm Holding Company Info

EPS Growth 5Y

7,30%

Market Cap

€2,54 B

Long-Term Debt

€0,89 B

Quarterly earnings

05/15/2026 (E)

Dividend

€0,90

Dividend Yield

1,90%

Founded

1991

Industry

Health Care

Country

Germany

Website

Dermapharm Holding

ISIN Number

DE000A2GS5D8

Website

http://ir.dermapharm.de

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

€46,00

-2.65%

Last Update: 04/04/2026

Analysts: 5

Highest Price Target €48,00

Average Price Target €46,00

Lowest Price Target €34,00

In the last five quarters, Dermapharm Holding’s Price Target has fallen from €65,40 to €56,75 - a -13,23% decrease. Two analysts predict that Dermapharm Holding’s share price will fall in the coming year, reaching €46,00. This would represent a decrease of -2,65%.

Top growth stocks in the health care sector (5Y.)

What does Dermapharm Holding do?

Dermapharm Holding SE (Dermapharm), together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany. Business Segments Dermapharm operates through three main business segments: Branded Pharmaceuticals and Other Healthcare Products, Herbal Extracts, and Parallel Import Business. Branded Pharmaceuticals and Other Healthcare Products: Within the Branded Pharmaceuticals and Other Healthcare Products segment, Dermapharm offers a diverse array of product...

Dermapharm Holding SE (Dermapharm), together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany.

Business Segments

Dermapharm operates through three main business segments: Branded Pharmaceuticals and Other Healthcare Products, Herbal Extracts, and Parallel Import Business.

Branded Pharmaceuticals and Other Healthcare Products: Within the Branded Pharmaceuticals and Other Healthcare Products segment, Dermapharm offers a diverse array of products targeting numerous therapeutic areas through well-recognized brand names. The company's focus is on the development, manufacturing, and marketing of these products, concentrating on selected markets where it typically maintains a substantial market share and can generate attractive profit margins.

Herbal Extracts: The Herbal Extracts segment is primarily delivered through Euromed S.A., a leading manufacturer in this field. This aspect of the business revolves around the production of herbal extracts and natural active ingredients, which serve as precursors for the manufacturing of phytopharmaceuticals, nutraceuticals, and cosmetics products. By capitalizing on this burgeoning area, Dermapharm positions itself as a key player in natural remedies and health solutions.

Parallel Import Business: Dermapharm’s Parallel Import Business, which operates under the distinguished ‘axicorp’ brand, leverages the legal requirement to import at least 5% of all prescription medications sold in Germany from other member states of the European Economic Area (EEA). This initiative serves to help minimize healthcare costs while simultaneously expanding the company's import capabilities. Although the financial performance and cash flows from the parallel import business segment are relatively modest, this operational facet contributes to Dermapharm’s overall strategic positioning within the healthcare landscape.

Business Strategy

The company's growth strategy heavily depends on strategic investments in research and development, with an emphasis on producing new products branded as ‘Made by Dermapharm.’ The focus of these research initiatives is primarily on developing compounds rooted in the company’s core therapeutic areas, utilizing active pharmaceutical ingredients that are largely free from intellectual property restrictions. Furthermore, Dermapharm is exploring opportunities in new patented therapies, specifically in the realm of hyperthermic products, which underscores its commitment to innovative healthcare solutions.

In the pursuit of its strategic objectives, Dermapharm is concentrated on fortifying its international presence and fueling organic growth. The company is investing in various development centers to enhance the research capabilities and bolster product offerings. Notable among these is the mibe F&E GmbH & Co. KG in Brehna, focused on pharmaceutical and analytical development, and the laboratory and innovation center operated by Euromed in Spain, which specializes in the development and commercial marketing of herbal extracts.

The organization employs a systematic evaluation process for measuring the success of business activities, utilizing performance indicators that are integrated into monthly management reporting. By continuously comparing planned outcomes against actual performance, the company is resilient in recognizing deviations and enacting corrective measures to stay aligned with revenue and EBITDA targets.

Products and Services

Dermapharm markets and develops a wide spectrum of products and services tailored to meet various healthcare needs. The range of offerings includes off-patent branded pharmaceuticals, which leverage established formulations and active ingredients recognized for efficacy. Within the non-prescription sector, Dermapharm provides over-the-counter drugs that are accessible to consumers, catering to a variety of ailments and health conditions.

In addition to pharmaceuticals, Dermapharm invests in the realm of natural solutions through its herbal extracts products. These offerings are integral to the formulation of phytotherapeutics and nutraceuticals, thereby tapping into the rising consumer preference for natural health products.

The organization also provides medical devices and the provision of parallel imports via the axicorp brand, demonstrating significant versatility in its market approach. The combined capabilities across the various segments illustrate Dermapharm’s commitment to delivering comprehensive health solutions catering to both conventional and alternative medicine.

Geographical Markets Served

Dermapharm has established a diverse geographical footprint that spans both domestic and international markets. The company’s subsidiaries operate predominantly in Germany while also maintaining a presence in Austria, Switzerland, Italy, Spain, Sweden, and various Eastern European nations including Croatia and Poland. Recently, Dermapharm has made strategic acquisitions to enhance its market presence and product range. The company remains focused on expanding its operations in other significant markets, ensuring a well-rounded approach to international growth.

Seasonality

Dermapharm's business exhibits certain seasonality, heavily influenced by the nature of the pharmaceutical and healthcare markets. Demand for various products may fluctuate based on seasonal health concerns such as flu seasons and allergy outbreaks. Consequently, the company adapts its manufacturing and marketing efforts to align with these seasonal peaks, promoting relevant products that cater to the changing needs of consumers throughout the year.

Customers

Dermapharm serves a diverse client base across various sectors within the healthcare industry. The company’s customers range from healthcare providers and pharmacies to direct consumers purchasing OTC and herbal products. The exact number of customers served is not solely documented, but the company maintains widespread market penetration, catering to a multitude of healthcare needs across geographic boundaries. Dermapharm's focus on wholesaling and direct-to-consumer sales channels further represents its commitment to accessibility and customer diversity.

Sales and Marketing

Dermapharm employs a multi-faceted approach to marketing, using a blend of traditional and digital channels to reach its customers. The company’s sales strategy encompasses direct outreach to healthcare professionals and partnerships with pharmacies to facilitate the distribution of its products. Additionally, leveraging online marketing techniques enhances Dermapharm's visibility and engagement with consumers. The diverse sales channels ensure that the company can effectively distribute its extensive product range to meet varying market needs.

History

Dermapharm Holding SE was founded in 1991. The company was incorporated in 2017.

Dermapharm Holding Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by sectors:** - **Pharmaceutical products:** approx. 70% - **Dietary supplements:** approx. 20% - **Cosmetic products:** approx. 10% **TOP 3 markets and their percentage shares:** - **Germany:** approx. 50% - **Austria:** approx. 15% - **Switzerland:** approx. 10% Dermapharm...

At which locations are the company’s products manufactured?

**Production Sites:** Germany, Spain, Italy Dermapharm Holding SE mainly produces its products in Germany, with several production facilities in the country. In addition, the company has also established production capacities in Spain and Italy. This geographical diversification enables Dermapharm...

What strategy does Dermapharm Holding pursue for future growth?

**Revenue Growth:** Estimated 10% annually (2026, based on historical data and market trends) **Focus on Internationalization:** Dermapharm Holding SE is increasingly focusing on internationalizing its products to tap into new markets and expand existing market shares. This includes both the Europe...

Which raw materials are imported and from which countries?

**Main raw materials:** Pharmaceutical active ingredients, packaging materials, excipients **Countries of origin:** China, India, Germany, Switzerland Dermapharm Holding SE imports a variety of raw materials necessary for the production of its pharmaceutical products. The most important materials...

How strong is the company’s competitive advantage?

**Market share in Germany:** 4.5% (2025) **Research and development ratio:** 7.2% of revenue (2025) **EBITDA margin:** 29.8% (2025) Dermapharm Holding SE has established itself as a significant player in the German pharmaceutical market. With a market share of 4.5% in 2025, the company demonstr...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 45% (2026, estimated) **Insider Purchases:** No significant purchases in the last year **Insider Sales:** 2.5 million euros (2026) The institutional investor share in Dermapharm Holding SE is estimated to be 45%. This indicates a solid interest from institutional...

What percentage market share does Dermapharm Holding have?

**Market share of Dermapharm Holding SE:** 3.2% (estimated, 2026) **Top competitors and their market shares:** 1. Bayer AG: 12.5% 2. Merck KGaA: 10.8% 3. Stada Arzneimittel AG: 9.4% 4. Teva Pharmaceutical Industries Ltd.: 8.7% 5. Sanofi: 7.9% 6. Dermapharm Holding SE: 3.2% 7. Hexal AG: 2.5% 8. Rati...

Is Dermapharm Holding stock currently a good investment?

**Revenue Growth:** 8.5% (2025) **EBITDA Margin:** 28.2% (2025) **R&D Expenditure Growth:** 12% (2025) Dermapharm Holding SE achieved solid revenue growth of 8.5% in 2025, attributed to strong demand for its products and successful market expansion. The EBITDA margin of 28.2% indicates that the...

Does Dermapharm Holding pay a dividend – and how reliable is the payout?

**Dividend yield:** 2.8% (2026, estimated) **Dividend history:** Continuous payout for several years Dermapharm Holding SE has been paying a consistent dividend in recent years, indicating a reliable dividend policy. The estimated dividend yield for 2026 is around 2.8%, which can be considered st...

New support ticket

Explore

Dermapharm Holding Stock Value

Dermapharm Holding Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Dermapharm Holding do?

Dermapharm Holding Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Dermapharm Holding Stock Value

Dermapharm Holding Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Dermapharm Holding do?

Dermapharm Holding Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.